No Data
Should We Be Delighted With Medexus Pharmaceuticals Inc.'s (TSE:MDP) ROE Of 11%?
Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (Treosulfan for Injection) in Quebec, Canada
Medexus Provides Update on Progress of Commercialization of GRAFAPEX (Treosulfan) for Injection
Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.
Positive Growth Outlook for Medexus Pharmaceuticals Inc. Amid Strategic Expansion and Stable Performance
Medexus Pharmaceuticals Inc. Cut to Hold From Buy by Stifel Nicolaus
